Filibuvir In Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Subjects

• Hepatitis
• Hepatitis C

• Drug: Filibuvir
  
  300 mg BID
• Drug: Filibuvir
  
  600 mg BID
• Drug: Placebo
  
  BID

• Experimental: Arm A
  

  Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)

  - or - Filibuvir 300 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)

  Intervention: Drug: Filibuvir
• Experimental: Arm B
  

  Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks (subjects with undetectable HCV RNA at week 4)

  - or - Filibuvir 600 mg BID + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks (subjects with detectable HCV RNA at week 4)

  Intervention: Drug: Filibuvir
• Placebo Comparator: Arm C
  
  Placebo + pegIFN/RBV x 24 weeks followed by pegIFN/RBV x 24 weeks
  Intervention: Drug: Placebo

Inclusion Criteria:

• Male or female subjects at least 18 years of age.
• HCV seropositive.
• HCV RNA >10,000 IU/mL at screening.
• HCV Genotype 1. Subjects infected with a non-genotype 1 strain or mixed genotypes are not eligible.
• Treatment naïve (no prior treatment with IFN alfa +/ RBV regimens or investigational anti-HCV agents).
• Liver biopsy within two years (24 months) of Screening with non-cirrhotic fibrosis classification. For those subjects with liver biopsy outside of the time window or for those subjects with no history of liver biopsy, a biopsy must be performed prior to randomization.
• Ultrasound within 6 months of Screening for 1) those subjects with bridging fibrosis or 2) those subjects with AFP >50 and <100 ng/mL with no evidence of hepatocellular carcinoma. For those subjects with an ultrasound conducted outside the 6-month time window, an ultrasound must be performed prior to randomization.

Exclusion Criteria:

• Co-infection with either HIV or HBV.
• Evidence of severe or decompensated liver disease.
• Subjects with liver disease unrelated to HCV infection.
• Pre-existing medical condition that makes the subject unsuitable for treatment with pegIFN/RBV therapy per product labeling.
• Laboratory abnormality at Screening that makes the subject unsuitable for treatment with pegIFN/RBV therapy per product labeling.
• Abnormal ECG suggestive of clinically significant cardiac disease or QTc>450msec.
• History of organ transplant.
• Contraindicated medications being taken by the subject at the time of randomization that must be continued during the study period, including potent CYP3A4 inhibitors, sensitive CYP3A4 substrates, CYP3A4 substrates with narrow therapeutic range and CYP3A4 inducers.
• Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up.
• Pregnant or nursing females.
• Males whose female partner is pregnant.